Topical Lipophilic Epigallocatechin-3-Gallate on Herpes Labialisa Phase II Clinical Trial of Averteax Formula

Document Type


Publication Date



Objective Previous in vitro and in vivo studies indicated that catechins from the tea plant (Camellia sinensis) have a therapeutic effect on herpes simplex virus infections. The aim of this study was to clinically evaluate a topical proprietary formulation containing lipophilic catechins (AverTeaX, Camellix, LLC, Evans, GA, USA) on recurrent herpes labialis. Study Design A double-blind, placebo-controlled, randomized trial with 40 participants, initially in two groups. Results Compared with the vehicle (100% glycerin USP, CVS Pharmacies, Inc., Woonsocket, RI, USA) group, AverTeaX applied topically six to eight times daily resulted in a significant reduction in clinical episode duration (median 4.5 days vs. 9 days; P =.003) and shortened blistering and ulceration stages within an episode from a median of 3 days to 1 day (P =.0003). Median quality-of-life scores, based on a multiquestion survey, showed significant differences between the groups with respect to duration of itching, from a median of 4 days to 1 day (P =.0021), and duration until symptom free, from a median of 8 days to 4 days (P =.0016). Significant differences were not found for median scores for itching, pain, burning, swelling, bleeding, and stress. Adverse effects were not reported. Conclusion AverTeaX formulation containing lipophilic catechins effectively inhibited herpes simplex labialis infection with clinical significance.



This document is currently not available here.